| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2024-01-17 |
4 |
D |
$119.13 |
$197,279 |
D/D |
(1,656) |
32,713 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,087 |
34,369 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2024-01-17 |
4 |
D |
$119.13 |
$1,458,747 |
D/D |
(12,245) |
402,058 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,545 |
414,303 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2023-12-04 |
4 |
S |
$119.27 |
$49,736 |
D/D |
(417) |
6,888 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2023-12-04 |
4 |
S |
$119.27 |
$49,736 |
D/D |
(417) |
6,888 |
|
- |
|
| Gala Renee D |
President & COO |
• – – |
2023-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
772 |
36,887 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-09-01 |
4 |
AS |
$144.25 |
$216,375 |
D/D |
(1,500) |
29,186 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-08-29 |
4 |
S |
$143.47 |
$20,373 |
D/D |
(142) |
5,986 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-08-15 |
4 |
S |
$139.59 |
$104,695 |
D/D |
(750) |
30,686 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
14,868 |
|
- |
|
| Oriordan Anne |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
12,551 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
7,305 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
20,946 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$185,685 |
D/D |
(1,344) |
16,778 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-08-14 |
4 |
S |
$138.16 |
$21,829 |
D/D |
(158) |
6,128 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
13,705 |
|
- |
|
| Gray Peter |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
16,068 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,454 |
D/D |
(1,241) |
7,305 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
10,444 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2023-08-14 |
4 |
S |
$138.16 |
$171,455 |
D/D |
(1,241) |
24,723 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
16,109 |
|
- |
|
| Oriordan Anne |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
13,792 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
8,546 |
|
- |
|
| Henderson Mary Elizabeth |
SVP, Technical Operations |
• – – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,763 |
10,763 |
|
- |
|
881 Records found
|
|
Page 2 of 36 |
|
|
0.37 (0.34%) 
